» Articles » PMID: 30728496

Neutrophils Escort Circulating Tumour Cells to Enable Cell Cycle Progression

Abstract

A better understanding of the features that define the interaction between cancer cells and immune cells is important for the development of new cancer therapies. However, focus is often given to interactions that occur within the primary tumour and its microenvironment, whereas the role of immune cells during cancer dissemination in patients remains largely uncharacterized. Circulating tumour cells (CTCs) are precursors of metastasis in several types of cancer, and are occasionally found within the bloodstream in association with non-malignant cells such as white blood cells (WBCs). The identity and function of these CTC-associated WBCs, as well as the molecular features that define the interaction between WBCs and CTCs, are unknown. Here we isolate and characterize individual CTC-associated WBCs, as well as corresponding cancer cells within each CTC-WBC cluster, from patients with breast cancer and from mouse models. We use single-cell RNA sequencing to show that in the majority of these cases, CTCs were associated with neutrophils. When comparing the transcriptome profiles of CTCs associated with neutrophils against those of CTCs alone, we detect a number of differentially expressed genes that outline cell cycle progression, leading to more efficient metastasis formation. Further, we identify cell-cell junction and cytokine-receptor pairs that define CTC-neutrophil clusters, representing key vulnerabilities of the metastatic process. Thus, the association between neutrophils and CTCs drives cell cycle progression within the bloodstream and expands the metastatic potential of CTCs, providing a rationale for targeting this interaction in treatment of breast cancer.

Citing Articles

Molecular Underpinnings of Brain Metastases.

Jacome M, Wu Q, Chen J, Mohamed Z, Mokhtari S, Pina Y Int J Mol Sci. 2025; 26(5).

PMID: 40076927 PMC: 11900073. DOI: 10.3390/ijms26052307.


Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.

Demir T, Moloney C, Mahalingam D Cancers (Basel). 2025; 17(5).

PMID: 40075563 PMC: 11898821. DOI: 10.3390/cancers17050715.


Neutrophils take their PICk to promote breast cancer.

Tulotta C, Soehnlein O Nat Cancer. 2025; .

PMID: 40075236 DOI: 10.1038/s43018-025-00925-2.


Neutrophils physically interact with tumor cells to form a signaling niche promoting breast cancer aggressiveness.

Camargo S, Moskowitz O, Giladi A, Levinson M, Balaban R, Gola S Nat Cancer. 2025; .

PMID: 40055573 DOI: 10.1038/s43018-025-00924-3.


Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.

Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X Cell Death Discov. 2025; 11(1):84.

PMID: 40032852 PMC: 11876437. DOI: 10.1038/s41420-025-02366-3.


References
1.
ROTHSTEIN G, Rhondeau S, Peters C, Christensen R, Lynch D, Gillis S . Stimulation of neutrophil production in CSF-1-responsive clones. Blood. 1988; 72(3):898-902. View

2.
Kacinski B, Scata K, Carter D, Yee L, Sapi E, King B . FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene. 1991; 6(6):941-52. View